Hybio Pharmaceutical and Sinopharm CNCM Sign Strategic Cooperation Agreement to Explore New Paths for Innovative Drug R&D
On April 29, 2025, Shenzhen Hybio Pharmaceutical Co., Ltd. (stock code: 300199, referred to as "Hybio"), Hybio Biotechnology (Dali) Co., Ltd. (referred to as "Hybio Dali") and Sinopharm Group Co., Ltd. (hereinafter referred to as "Sinopharm") held a strategic cooperation agreement signing ceremony in Shenzhen. The two parties will carry out in-depth cooperation in areas such as cannabidiol (CBD) innovative drug research and development, technical integration of peptide and small nucleic acid drugs, and commercial promotion. This cooperation marks an important step in China's pharmaceutical industry's exploration of plant-sourced innovative drug research and development under the compliance framework, injecting new impetus into the high-quality development of the pharmaceutical industry.
Yu Pinxiang, Director and Executive President of Hybio Pharmaceutical, and Tang Lei, Deputy General Manager of Sinopharm, signed the agreement on behalf of both parties. Present at and witnessing the signing ceremony were Zeng Shaogui, Chairman and President of Hybio Pharmaceutical; Tang Yangming, Director and Vice President; Yang Di, Director, Vice President and Secretary of the Board; as well as Tian Guotao, General Manager of Sinopharm; Liu Wendong, Director of Innovation and Development Department and Investment Department; Lu Guanming, BD Supervisor of Innovation and Development Department, and other leaders.
Focusing on Policy Orientation, Jointly Exploring New Paths for Innovative Drug R&D
In recent years, with the approval of relevant drugs in the EU and U.S. markets, cannabidiol (CBD) products have gradually gained market recognition. Hybio Dali has taken the lead in obtaining the renewal of the industrial hemp processing license, and in February 2025, it became the first domestic enterprise to submit a research and development project application for cannabidiol (CBD) API and oral liquid, officially initiating the compliance exploration of medicinal cannabidiol (CBD).
According to the agreement, relying on Hybio Pharmaceutical's peptide conjugation technology platform and Sinopharm's national network channels, both parties will jointly promote the research and development of cannabidiol (CBD) in innovative drugs and improved new drugs. The cooperation will strictly comply with relevant regulatory requirements to ensure that the project achieves technological breakthroughs within the scope permitted by policies.
Leveraging Synergies to Empower Innovation and Upgrading in the Pharmaceutical Industry
Mr. Zeng Shaogui, Chairman and President of Hybio Pharmaceutical, stated, "This cooperation is an important practice of Hybio Pharmaceutical's 'combination of innovation and imitation' strategy. With the support of Sinopharm, we will give full play to our technical advantages in the fields of industrial hemp, peptides, and small nucleic acid drugs, explore breakthroughs in innovative drugs from R&D and Clinical Trials to marketization, and provide patients with safer and more effective treatment options."
Mr. Tian Guotao, General Manager of Sinopharm, pointed out, "As a national pharmaceutical enterprise, Sinopharm has always put people's health first. We look forward to further promoting the high-quality development of the specialty pharmaceutical industry through cooperation with Hybio Pharmaceutical."
Looking Ahead to Cooperation Prospects and Building an Integrated Industry-University-Research-Application Ecosystem
According to the agreement, Hybio Pharmaceutical, Hybio Dali and Sinopharm will carry out in-depth collaboration in areas such as technical R&D cooperation, joint project application, clinical resource sharing, market expansion and commercialization, as well as intellectual property and achievement sharing.
The two parties plan to jointly promote the development of multiple innovative drugs and improved new drugs, which are expected to fill the gaps in relevant domestic fields and provide more safe and effective treatment options for global patients.
This cooperation is not only an active response to the national policy of encouraging pharmaceutical innovation, but also a concrete implementation of the goal of "strengthening research and development of botanical drugs" in the 14th Five-Year Plan for the Development of the Pharmaceutical Industry. Adhering to a people-centered approach to health and taking meeting clinical needs as the starting point, both parties will jointly explore and build an integrated "government-industry-university-research-application" innovation ecosystem, contributing wisdom and strength to the high-quality development of the pharmaceutical industry.